[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601379":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":11,"centralContacts":36,"locations":42,"responsibleParty":254,"collaborators":11,"id":256,"slug":11,"hasResults":257,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":11,"eligibilityCriteria":260,"healthyVolunteers":257,"sex":261,"minAge":262,"maxAge":11,"enrollmentInfo":263,"targetDuration":11,"studyType":266,"phases":267,"briefSummary":270,"conditions":271,"keywords":280,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":293},{"fullName":5,"class":6},"Terremoto Biosciences Inc.","INDUSTRY",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Monotherapy Dose Escalation","EXPERIMENTAL",null,[13],"Drug: TER-2013",{"label":15,"type":10,"description":16,"interventionNames":17},"Combination Therapy Dose Escalation","Dose Escalation of TER-2013 with recommended dose of fulvestrant",[13,18],"Drug: Fulvestrant injection",{"label":20,"type":10,"description":11,"interventionNames":21},"Monotherapy Dose Expansion",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Combination Therapy Dose Expansion","Dose Expansion of TER-2013 with recommended dose of fulvestrant",[13,18],[27,32],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","TER-2013","Oral Capsules",[15,23,9,20],{"type":28,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"Fulvestrant injection","Fulvestrant 500 mg Intramuscular Injection",[15,23],[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Terremoto Biosciences, Inc. Clinical Trials Central Contact","CONTACT","888-682-1551","clinicaltrials@terremotobio.com",[43,61,71,86,101,116,131,144,159,174,186,199,213,225,240],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Florida Cancer Specialists - Lake Nona","RECRUITING","Orlando","Florida","32827","United States",{"type":51,"coordinates":52},"Point",[53,54],-81.37924,28.53834,{"lat":54,"lon":53},[57],{"name":58,"role":39,"phone":59,"phoneExt":11,"email":60},"Elizabeth Griffith- Gilmore","904-380-2418","elizabeth.griffith@scri.com",{"facility":62,"status":45,"city":63,"state":64,"zip":65,"country":49,"cosmosGeoPoint":66,"geoPoint":70,"contacts":11},"Massachusetts General Hospital","Boston","Massachusetts","02144",{"type":51,"coordinates":67},[68,69],-71.05977,42.35843,{"lat":69,"lon":68},{"facility":72,"status":45,"city":73,"state":74,"zip":75,"country":49,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Mayo Rochester","Rochester","Minnesota","55905",{"type":51,"coordinates":77},[78,79],-92.4699,44.02163,{"lat":79,"lon":78},[82],{"name":83,"role":39,"phone":84,"phoneExt":11,"email":85},"Clinical Research Recruitment","507-284-2511","mayocliniccancerstudies@mayo.edu",{"facility":87,"status":45,"city":88,"state":89,"zip":90,"country":49,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Washington Univ. School of Medicine","St Louis","Missouri","63110",{"type":51,"coordinates":92},[93,94],-90.19789,38.62727,{"lat":94,"lon":93},[97],{"name":98,"role":39,"phone":99,"phoneExt":11,"email":100},"Study Coordinator","800-600-3606","enix@wustl.edu",{"facility":102,"status":45,"city":103,"state":104,"zip":105,"country":49,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Nebraska Cancer Specialists","Omaha","Nebraska","68130",{"type":51,"coordinates":107},[108,109],-95.94043,41.25626,{"lat":109,"lon":108},[112],{"name":113,"role":39,"phone":114,"phoneExt":11,"email":115},"Ashley Servais Degenhardt","402-955-2691","aservais@nebraskacancer.com",{"facility":117,"status":45,"city":118,"state":119,"zip":120,"country":49,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Carolina BioOncology Institute","Huntersville","North Carolina","28078",{"type":51,"coordinates":122},[123,124],-80.84285,35.41069,{"lat":124,"lon":123},[127],{"name":128,"role":39,"phone":129,"phoneExt":11,"email":130},"Ryan Allen","704-947-6599","info@carolinabioooncology.org",{"facility":132,"status":45,"city":133,"state":134,"zip":135,"country":49,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"UH Cleveland Medical Center","Cleveland","Ohio","44106",{"type":51,"coordinates":137},[138,139],-81.69541,41.4995,{"lat":139,"lon":138},[142],{"name":11,"role":39,"phone":143,"phoneExt":11,"email":11},"833-788-7425",{"facility":145,"status":45,"city":146,"state":147,"zip":148,"country":49,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Sarah Cannon Nashville","Nashville","Tennessee","37203",{"type":51,"coordinates":150},[151,152],-86.78444,36.16589,{"lat":152,"lon":151},[155],{"name":156,"role":39,"phone":157,"phoneExt":11,"email":158},"Referral Coordinator","615.329.7274","asksarah@scresearch.net",{"facility":160,"status":45,"city":161,"state":162,"zip":163,"country":49,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"NEXT Oncology","Austin","Texas","78229",{"type":51,"coordinates":165},[166,167],-97.74306,30.26715,{"lat":167,"lon":166},[170],{"name":171,"role":39,"phone":172,"phoneExt":11,"email":173},"Recruitment Coordinator","737-610-5200","NXTAUS_Coordinators@nextoncology.com",{"facility":175,"status":45,"city":176,"state":162,"zip":177,"country":49,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"MD Anderson Cancer Center","Houston","77030",{"type":51,"coordinates":179},[180,181],-95.36327,29.76328,{"lat":181,"lon":180},[184],{"name":11,"role":39,"phone":185,"phoneExt":11,"email":11},"877-589-0209",{"facility":187,"status":45,"city":188,"state":162,"zip":163,"country":49,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"START Center for Cancer Research","San Antonio",{"type":51,"coordinates":190},[191,192],-98.49363,29.42412,{"lat":192,"lon":191},[195],{"name":196,"role":39,"phone":197,"phoneExt":11,"email":198},"Isabel Jimenez","210-593-5265","isabel.jimenez@startresearch.com",{"facility":187,"status":45,"city":200,"state":201,"zip":202,"country":49,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"West Valley City","Utah","84119",{"type":51,"coordinates":204},[205,206],-112.00105,40.69161,{"lat":206,"lon":205},[209],{"name":210,"role":39,"phone":211,"phoneExt":11,"email":212},"Marie Assay","801-907-4770","marie.asay@startresearch.com",{"facility":160,"status":45,"city":214,"state":215,"zip":216,"country":49,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"Fairfax","Virginia","22031",{"type":51,"coordinates":218},[219,220],-77.30637,38.84622,{"lat":220,"lon":219},[223],{"name":156,"role":39,"phone":224,"phoneExt":11,"email":173},"(703) 783-4518",{"facility":226,"status":45,"city":227,"state":228,"zip":229,"country":49,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"Froedtert & MCW Cancer Center","Milwaukee","Wisconsin","53226",{"type":51,"coordinates":231},[232,233],-87.90647,43.0389,{"lat":233,"lon":232},[236],{"name":237,"role":39,"phone":238,"phoneExt":11,"email":239},"John Charlson","414-805-8900","jcharlson@mcw.edu",{"facility":241,"status":45,"city":242,"state":11,"zip":243,"country":244,"cosmosGeoPoint":245,"geoPoint":249,"contacts":250},"PanOncology Trials","San Juan","00935","Puerto Rico",{"type":51,"coordinates":246},[247,248],-66.10572,18.46633,{"lat":248,"lon":247},[251],{"name":98,"role":39,"phone":11,"phoneExt":252,"email":253},"787-407-3333","info@panoncologytrials.com",{"type":255,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601379",false,"NCT07109726","A Phase 1\u002F2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT\u002FPI3K\u002FPTEN Pathway Alterations","Key Inclusion Criteria\n\n* Metastatic or locally advanced, unresectable disease\n* No available treatment with curative intent\n* Presence of lesions to be evaluated per RECIST v1.1:\n\n  a. Dose Escalation: measurable or evaluable disease b. Cohort Expansion: measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\n* Advanced solid tumor malignancy harboring an eligible AKT\u002FPI3K\u002FPTEN pathway alteration detected by a sponsor approved test\n\nKey Inclusion Criteria for TER-2013 monotherapy arms:\n\n* Histologically confirmed diagnosis of:\n\n  a. \\[For TER-2013 dose escalation\\]: solid tumor malignancy b. \\[For TER-2013 cohort expansion\\]: i. Cohort 1: ovarian cancer, cervical cancer, or squamous cell carcinoma of the head and neck, lung, or esophagus ii. Cohort 2: endometrial adenocarcinoma\n* Prior therapy:\n\n  1. \\[For TER-2013 dose escalation\\]: Received standard therapies appropriate for their tumor type and stage, unless contraindicated, intolerable, or patient refused\n  2. \\[For TER-2013 cohort expansion\\]: No more than 3 prior lines of treatment in the advanced setting\n\n     Key Inclusion Criteria for TER-2013 and fulvestrant combination arms\n* Histologically confirmed diagnosis of:\n\n  a. \\[For TER-2013 + fulvestrant dose escalation\\]: HR+\u002FHER2- advanced unresectable or metastatic breast cancer b. \\[For TER-2013 + fulvestrant cohort expansion\\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting\n* Prior Therapy:\n\n  a. \\[For TER-2013 + fulvestrant dose escalation\\]: Received treatment with an AI containing regimen (single agent or in combination) b. \\[For TER-2013 + fulvestrant cohort expansion\\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting\n\nKey Exclusion Criteria:\n\n* Known EGFR, KRAS, NRAS, HRAS, or BRAF oncogenic-driver co-mutation with PI3K\u002FAKT\u002FPTEN alteration\n* Clinically significant abnormalities of glucose metabolism\n* Active brain metastases or carcinomatous meningitis.\n* History of significant hemoptysis or hemorrhage within 4 weeks prior to first dose of study drug\n* Malabsorption syndrome, nausea and vomiting uncontrolled by medication, or disease significantly affecting gastrointestinal function likely to interfere with the delivery, absorption, or metabolism of TER-2013\n* Prior therapy:\n\n  1. \\[For TER-2013 monotherapy escalation\\]: AKT inhibitor\n  2. \\[For TER-2013 monotherapy expansion\\]: AKT\u002FPI3K\u002FPTEN pathway inhibitor\n  3. \\[For TER-2013 + fulvestrant combination expansion\\]: AKT\u002FPI3K\u002FPTEN pathway inhibitor, fulvestrant and other SERDs, mTOR inhibitor; some PIK3CA-altered cohorts allow prior PI3K inhibitor.\n\nOther protocol-defined Inclusion\u002FExclusion Criteria apply","ALL","18 Years",{"count":264,"type":265},205,"ESTIMATED","INTERVENTIONAL",[268,269],"PHASE1","PHASE2","This is a Phase 1\u002F2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT\u002FPI3K\u002FPTEN pathway alterations.",[272,273,274,275,276,277,278,279],"Breast Cancer","Endometrial Cancer","Ovarian Cancer","Lung Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Esophageal Squamous Cell Carcinoma","Solid Tumor","Cervical Cancer",[281,272,282,283],"AKT\u002FPI3K\u002FPTEN Alterations","Advanced Solid Tumors","HR+\u002FHER2-","2026-05-20",{"date":286,"type":287},"2026-05-22","ACTUAL",{"date":289,"type":287},"2025-09-23",{"date":291,"type":265},"2029-02-28",{"name":5,"class":6},15]